Table of Contents Author Guidelines Submit a Manuscript
Neurology Research International
Volume 2016, Article ID 7685807, 7 pages
Review Article

Utility of Plasmapheresis in Autoimmune-Mediated Encephalopathy in Children: Potentials and Challenges

Department of Pediatrics, Division of Pediatric Neurology, Hamad Medical Corporation, Doha, Qatar

Received 23 February 2016; Revised 31 March 2016; Accepted 10 April 2016

Academic Editor: Di Lazzaro Vincenzo

Copyright © 2016 Abdulhafeez M. Khair. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Autoimmune-mediated encephalopathy in children continues to constitute a diagnostic and therapeutic challenge in pediatric population. Utility and usefulness in this clinical setting of plasmapheresis have seldom been evaluated in current pediatric literature. Children with immune-mediated encephalopathies represent a uniquely different group among patients presenting to intensive care units or neurological services worldwide. Arriving at a final diagnosis is not an easy task for treating physicians. It is very crucial to consider early use of first-line immunotherapy modalities, save those children’s lives and improve outcomes. Plasmapheresis is an emerging, potentially beneficial first-line therapy in such patients. However, indications, value, logistics, and procedural difficulties are often faced. This study is mainly meant to review the current knowledge in regard to the clinical value of plasmapheresis in children with immune-mediated encephalopathy.